Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 88-92 |
| Number of pages | 5 |
| Journal | Journal of Geriatric Cardiology |
| Volume | 8 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2011 |
| Externally published | Yes |
Fingerprint
Cite this
}
Adherence to treatment guidelines in the pharmacological management of chronic heart failure in an Australian population. / Yao, Dao-Kuo; Wang, Le-Xin; Curran, Shane; Ball, Patrick.
In: Journal of Geriatric Cardiology, Vol. 8, No. 2, 2011, p. 88-92.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Adherence to treatment guidelines in the pharmacological management of chronic heart failure in an Australian population
AU - Yao, Dao-Kuo
AU - Wang, Le-Xin
AU - Curran, Shane
AU - Ball, Patrick
PY - 2011
Y1 - 2011
N2 - Background To document the pharmacotherapy of chronic heart failure (CHF) and to evaluate the adherence to treatment guidelines in Australian population. Methods The pharmacological management of 677 patients (female 46.7%, 75.5 ± 11.6 years) with CHF was retrospectively analyzed. Results The use of angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARB) and β-blockers were 58.2 % and 34.7 %, respectively. Major reasons for non-use of ACE inhibitors/ARBs were hyperkalemia and elevated serum creatinine level. For patients who did not receive β-blockers, asthma and chronic obstructive pulmonary disease were the main contraindications. Treatment at or above target dosages for ACE inhibitors/ARBs and β-blockers was low for each medication (40.3% and 28.9%, respectively). Conclusions Evidenced-based medical therapies for heart failure were under used in a rural patient population. Further studies are required to develop processes to improve the optimal use of heart failure medications.
AB - Background To document the pharmacotherapy of chronic heart failure (CHF) and to evaluate the adherence to treatment guidelines in Australian population. Methods The pharmacological management of 677 patients (female 46.7%, 75.5 ± 11.6 years) with CHF was retrospectively analyzed. Results The use of angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARB) and β-blockers were 58.2 % and 34.7 %, respectively. Major reasons for non-use of ACE inhibitors/ARBs were hyperkalemia and elevated serum creatinine level. For patients who did not receive β-blockers, asthma and chronic obstructive pulmonary disease were the main contraindications. Treatment at or above target dosages for ACE inhibitors/ARBs and β-blockers was low for each medication (40.3% and 28.9%, respectively). Conclusions Evidenced-based medical therapies for heart failure were under used in a rural patient population. Further studies are required to develop processes to improve the optimal use of heart failure medications.
UR - http://www.scopus.com/inward/record.url?scp=79959939864&partnerID=8YFLogxK
U2 - 10.3724/SP.J.1263.2011.00088
DO - 10.3724/SP.J.1263.2011.00088
M3 - Article
VL - 8
SP - 88
EP - 92
JO - Journal of Geriatric Cardiology
JF - Journal of Geriatric Cardiology
SN - 1671-5411
IS - 2
ER -